
Biogen (BIIB) Stock Forecast & Price Target
Biogen (BIIB) Analyst Ratings
Bulls say
Biogen is a established biopharmaceutical company with a diverse portfolio of drugs targeting neurodegenerative and rare diseases. Positive clinical trial data and increased usage of blood-based diagnostics have led to an upgrade to a Buy rating and potential sales of over $7 billion. The company's estimated peak sales for Leqembi is $2 billion and they are considered a sustainability model in the industry, but face risks such as competition and pricing pressure.
Bears say
Biogen is facing several headwinds, including a declining multiple sclerosis franchise, with its newer franchises still in early stages of development and not expected to contribute significantly to revenue growth in the next few years. The recently announced data for BIIB080 and discontinuation of development of BIIB122 add to the uncertainty surrounding Biogen's pipeline. European NMD-ARO prices cannibalizing US Spinraza sales along with biosimilar competition are also looming threats for the company's top line.
This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.
Biogen (BIIB) Analyst Forecast & Price Prediction
Start investing in Biogen (BIIB)
Order type
Buy in
Order amount
Est. shares
0 shares